Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
复制标题
DOI:
10.1021/jm5003588
复制
发表时间:
2014-07-24
影响因子:
7.3
通讯作者:
Lee KH
中科院分区:
文献类型:
--
作者:
Wang MJ;Liu YQ;Chang LC;Wang CY;Zhao YL;Zhao XB;Qian K;Nan X;Yang L;Yang XM;Hung HY;Yang JS;Kuo DH;Goto M;Morris-Natschke SL;Pan SL;Teng CM;Kuo SC;Wu TS;Wu YC;Lee KH
Twelve novel 20-sulfonylamidine derivatives (9a–9l) of camptothecin (1) were synthesized via a Cu-catalyzed three-component reaction. They showed similar or superior cytotoxicity compared with that of irinotecan (3) against A-549, DU-145, KB, and multidrug-resistant (MDR) KBvin tumor cell lines. Compound 9a demonstrated better cytotoxicity against MDR cells compared with that of 1 and 3. Mechanistically, 9a induced significant DNA damage by selectively inhibiting Topoisomerase (Topo) I and activating the ATM/Chk related DNA damage-response pathway. In xenograft models, 9a demonstrated significant activity without overt adverse effects at 5 and 10 mg/kg, comparable to 3 at 100 mg/kg. Notably, 9a at 300 mg/kg (i.p.) showed no overt toxicity in contrast to 1 (LD50 56.2 mg/kg, i.p.) and 3 (LD50 177.5 mg/kg, i.p.). Intact 9a inhibited Topo I activity in a cell-free assay in a manner similar to that of 1, confirming that 9a is a new class of Topo I inhibitor. 20-Sulfonylamidine 1-derivative 9a merits development as an anticancer clinical trial candidate.
登录
查看更多内容
影响因子:
7.3
作者:
Rahmathullah, SM;Hall, JE;Boykin, DW
通讯作者:
Boykin, DW
影响因子:
7.3
作者:
Lerchen, HG;Baumgarten, J;Fiebig, HH
通讯作者:
Fiebig, HH
影响因子:
--
作者:
Greenhill, J V;Lue, P
通讯作者:
Lue, P
影响因子:
6.7
作者:
Sondhi, Sham M.;Dinodia, Monica;Kumar, Ashok
通讯作者:
Kumar, Ashok
影响因子:
4.8
作者:
Takemura, Haruyuki;Rao, V. Ashutosh;Pommier, Yves
通讯作者:
Pommier, Yves